Of note, VIP amino acid sequence is identical between humans and mice, and VIP-R sequences are highly conserved77, suggesting the VIP-R antagonists with immunological activity in tumor-bearing mice may have comparable properties in human patients. Here, VIPR1 is linked to neoplasm.